Bristol Myers Squibb Showcases Positive Results Of New Phase 3 Study Evaluating Cancer Drug Opdivo | Latest News RSS feed

Bristol Myers Squibb Showcases Positive Results Of New Phase 3 Study Evaluating Cancer Drug Opdivo - Latest News


Bristol Myers Squibb showcases positive results of new Phase 3 study evaluating cancer drug Opdivo

The pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) today revealed positive results from a new study evaluating its lead cancer drug Opdivo. The pharma company’s Phase 3 CheckMate-227 trial evalu... read more

Wired News – Bristol-Myers Squibb’s Phase-3 CheckMate-227 Study Met its Co-Primary Endpoint

On February 05, 2018, the Company declared that the ongoing Phase-3 CheckMate-227 study assessing the combination of Opdivo (nivolumab ... a Breakthrough in Cancer Research Giovanni Caforio, M.D., Cha... read more

Bristol-Myers Squibb reports positive results from CheckMate -214 phase 3 study of Opdivo in combo with Yervoy to treat advanced/metastatic RCC

Bristol-Myers Squibb Company announced topline results from the CheckMate -214 ... CheckMate -214 is a phase 3, randomized, open-label study evaluating the combination of Opdivo plus Yervoy versus sun... read more

Looking for another news?


Unique combination of Opdivo + Yervoy shows encouraging action in Phase 1/2 bladder cancer study

Follow-up data from a Phase 1/2 clinical trial, CheckMate-032, evaluating Bristol-Myers Squibb's (NYSE:BMY) Opdivo ... No new safety signals were observed. The data support the ongoing Phase 3 CheckMa... read more


Bristol-Myers Squibb’s new dosing for cancer drug Opdivo gets FDA green light

Bristol-Myers Squibb Co (NYSE:BMY) said the US Food and Drug Administration (FDA) has given the green light for a new dosing schedule for its drug Opdivo, for a number of ... the deputy director of th... read more

Bristol-Myers Squibb Showcases Rheumatoid Arthritis and Immunoscience Commitment with Depth of Research at 2016 American College of Rheumatology and Association of Rheumatology ...

New PsA and pJIA Data Among Bristol-Myers Squibb Presentations ... will reveal topline results from the ASTRAEA (Active pSoriaTic aRthritis rAndomizEd triAl) study, an international, double-blind, mul... read more

Bristol-Myers Squibb announces positive results from phase 3 CheckMate -214 trial of Opdivo plus low-dose Yervoy in patients with advanced RCC

Bristol-Myers Squibb Company announced patient-reported ... Annual Meeting 2018 in Chicago CheckMate -214 is a Phase 3, randomised, open-label study evaluating the combination of Opdivo plus Yervoy ve... read more

Beyondspring Provides Operational Update and Second-Quarter 2018 Financial Results

“We are now looking ahead to reporting interim data from our Phase 3 Study 105 before year end. If positive, we plan to submit a New Drug ... and Bristol-Myers Squibb's PD-1 antibody, Opdivo ... read more

Why Is Bristol-Myers Squibb (BMY) Up 1.3% Since Its Last Earnings Report?

It has been about a month since the last earnings report for Bristol-Myers Squibb ... cancer (mCRC). Story Continues The company also announced data from the phase III study, CheckMate-078, evaluating ... read more

Wired News – Bristol-Myers Squibb’s Phase-3 CheckMate-227 Study Met its Co-Primary Endpoint

Data from CheckMate-227 is a Breakthrough in Cancer Research Giovanni Caforio, M.D., Chairman and CEO of Bristol-Myers Squibb ... Phase-3 trial with more than 2,500 patients randomized across non-squa... read more

Bristol-Myers Squibb (BMY) Q1 2017 Results - Earnings Call Transcript

We shared important new data from our immuno-oncology portfolio at AACR [American Association of Cancer Research], including overall survival data from Study ... 4 molecule in Phase 3 trials. Thank yo... read more

Bristol-Myers Squibb Reports Third Quarter Financial Results

THIRD QUARTER FINANCIAL RESULTS THIRD QUARTER ... which grew 15%. Opdivo Yervoy Orencia BUSINESS DEVELOPMENT UPDATE NEW SHARE REPURCHASE Bristol-Myers Squibb today announced its Board of Directors app... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us